2-(1H-imidazol-1-yl)-N-{2'-[2-(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}phenoxy)ethyl]biphenyl-2-yl}acetamide | 1333937-55-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(1H-imidazol-1-yl)-N-{2'-[2-(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}phenoxy)ethyl]biphenyl-2-yl}acetamide
• 英文别名: 2-imidazol-1-yl-N-[2-[2-[2-[4-(pyridin-3-ylmethylcarbamoylamino)phenoxy]ethyl]phenyl]phenyl]acetamide
• CAS: 1333937-55-5
• 化学式: C₃₂H₃₀N₆O₃
• 分子量: 546.629
• InChiKey: YLYYQXOFPSVCSX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  41
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  110
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• COMPOUNDS AND THERAPEUTIC USES THEREOF
  申请人：Willardsen J. Adam

  公开号：US20150353538A1

  公开（公告）日：2015-12-10

  The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.
• THERAPEUTIC AND DIAGNOSTIC METHODS
  申请人：Fleischer Tracey C.

  公开号：US20160367541A1

  公开（公告）日：2016-12-22

  The invention relates to methods of treating diseases, particularly cancers, that respond favorably to the inhibition of Nicotinamide phosphoribosyltransferase (Nampt); it also relates to therapeutic methods that utilize Nampt inhibitors in combination with NAD biosynthesis precursors to intentionally kill cancer cells while limiting or minimizing toxicity to normal host cells; and it relates to methods of identifying cancers that will be most responsive to treatment with Nampt inhibitors, particularly when administered in combination with nicotinic acid.
• US8912184B1
  申请人：——

  公开号：US8912184B1

  公开（公告）日：2014-12-16